Skip to main content
. Author manuscript; available in PMC: 2023 May 23.
Published in final edited form as: Leukemia. 2020 Sep 11;35(6):1777–1781. doi: 10.1038/s41375-020-01036-w

Figure 2: KrasLSL-G12D/+.Mb1Cre/+ T-ALL/T-LLy has a short latency, causes disease in secondary recipients, and blasts are sensitive to standard chemotherapy agents.

Figure 2:

(A) KrasLSL-G12D/+.Mb1Cre/+ mice developed T-ALL/T-LLy and died at a median of 97 days (range 75-139 days). (B) NSG mice transplanted with primary KrasLSL-G12D/+.Mb1Cre/+ T-ALL (mouse 347) and T-LLy (mouse 349) blasts died with median latencies of 10 and 14 days, respectively. (C) Thymic blasts from three leukemic KrasLSL-G12D/+.Mb1Cre/+ mice (285, 302, 314) were incubated for 48 hours with varying concentrations of standard T-ALL/T-LLy chemotherapy agents vincristine (VCR), doxorubicin (DOX), and dexamethasone (DEX), followed by viability determination with ATP assay. Error bars for each point show standard deviation. (D) Each case demonstrated chemosensitivity, with IC50 values in the low nanomolar range.